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1. Introduction
Sarcoidosis is an inflammatory granulomatous disease that can affect multiple organ systems,
most commonly the lungs. It can also affect other organs, such as the nervous system and heart.
Although the exact etiology of sarcoidosis is unknown, it involves the development of
noncaseating granulomas in various organs. Noncaseating epithelioid granulomas are the
pathological hallmarks of sarcoidosis and symbolize the inflammatory sign of the disease.
granulomas are structured masses of activated macrophages and their derivatives (i.e.,
epitheloid and giant cells). Neurosarcoidosis is a manifestation of sarcoidosis specifically in
the nervous system. It is caused by inflammation and abnormal cell deposits in the central and/
or peripheral nervous system, including the brain, spinal cord, or peripheral nerves. In this
chapter, we intend to give a brief overview of the common neurologic manifestations of
sarcoidosis, as well as diagnosis and management of these symptoms. We will also discuss
management of steroid resistant neurosarcoidosis and atypical cases, as well as the overall
prognosis of the disease.
2. Epidemiology
Cases of sarcoidosis have been reported worldwide, with a prevalence of approximately 10-80
cases per 100,000 in North America and Europe. Within the United States, African Americans
have a greater lifetime risk of developing sarcoidosis than Caucasians (2.4% vs. 0.85%).
Worldwide, females have a slightly greater risk of developing this disease. The incidence of
sarcoidosis can be described as having a bimodal pattern, with most cases occurring between
the ages of 20-40 years old and a second commonly affected group being females who are over
the age of 50 [1].
© 2013 Kurukumbi et al.; licensee InTech. This is an open access article distributed under the terms of the
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About 5-16% of patients with sarcoidosis have neurologic involvement. The most frequent
neurologic abnormality includes cranial and peripheral neuropathy, followed by mononeurop‐
athy, myopathy, psychiatric disorders, cerebellar ataxia, hydrocephalus and papilledema.
Neurosarcoidosis is also more prevalent in people of African descent and uncommon in people
of Chinese descent and Southeast Asians. It is estimated that isolated neurosarcoidosis, without
clinical evidence of systemic sarcoidosis, occurs in less than 1% of sarcoidosis patients [2].
3. History
Sarcoidosis was first clinically described in 1878 by a dermatologist Dr. Johnathan Hutchinson,
who called the disease ‘Mortimer's Malady’, in reference to his patient’s name [3]. He wanted
to prove it by a biopsy but the patient refused. Then in 1889, Dr. Ernest Besnier described a
similar case which he called lupus pernio due to the “chillblain-like swelling” of the nose and
the lupus-vulgaris appearance of the fingers. Besnier also did not have histologic findings. It
was not until 1892, Tenneson showed a second case of lupus pernio accompanied by histo‐
logical studies showing lesions which contained epithelioid cells and giant cells. This was the
first description of a sarcoid granuloma. Cesar Boeck, in 1899, called it `Multiple Benign
Sarkoid of Skin’ which later gave birth to the term ‘sarcoidosis’. A few years later, central
nervous system (CNS) involvement by sarcoidosis was recognized in 1905 by Winkler [3].
4. Etiology and pathogenesis
Currently, the etiology of sarcoidosis is unknown. There have been hypotheses made including
infectious agents, occupational/environmental factors, genetic factors and autoimmune
disorders. There has not been a specific pathogen or pathogenic agent linked to the disease.
One thought is that the inflammatory response in sarcoidosis, which is characterized by large
numbers of activated macrophages and T lymphocytes bearing the CD4-helper phenotype,
along with cytokine production is most consistent with a Th1-type immune response com‐
monly triggered by antigens [4]. Also, seeing the trends of blacks and family clusters having
increased numbers of the disease, there is a possibility that it is genetic. Many patients with
sarcoidosis have the HLA-Factor B 8 (on chromosome 6) and DR 3. Another theory includes
inhalation of an antigen that causes granulomatous inflammation in mediastinal lymph nodes
and then extends to the lungs and other tissues.[5] Environmental factors involve infections,
such as Mycobacterium tuberculosis and Propionibacterium acnes or P. granulosum and non-
infectious environmental exposures, such as pesticides and insecticides, pine pollen, silica or
talc, metal dusts, and man-made mineral fibers. Exposure to these factors can cause diseases
that are histologically and clinically indistinguishable from sarcoidosis [4].
Neurosarcoidosis and multiple sclerosis can present with similar symptoms, such as optic
neuritis. It is important to be able to differentiate the two, due to different responses to
management and therapy. Since sarcoidosis is often a multisystem disease, solitary nervous-
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system sarcoidosis is difficult to diagnose, which may delay treatment. The neurological
symptoms make it a serious and commonly devastating complication of sarcoidosis [6].
5. Clinical manifestations of neurosarcoidosis
Neurosarcoidosis is seen in approximately 5% of sarcoidosis patients. Of these patients, some
may have neurological findings on initial presentation, while others present de novo with
neurological signs and symptoms that are consistent with a diagnosis of sarcoidosis [7]. Onset
of neurosarcoidosis is most common in the fourth or fifth decades, and typically occurs after
patients have had systemic symptoms for some time.
5.1. Cranial nerve findings
Cranial  mononeuropathies  frequently  occur  in  neurosarcoidosis.  In  2009,  Joseph  and
Scolding conducted a study of 30 new cases of sarcoidosis, and reported cranial neuropa‐
thies in 80% of the patients [8]. The 7th  cranial nerve is often affected. In fact, peripheral
facial nerve palsy has been noted in up to 50% of patients with neurosarcoidosis. Often‐
times, Bell palsy is found to be the first manifestation of sarcoidosis and may resolve prior
to development of additional symptoms. While facial neuropathies may arise due to basilar
meningitis, some cases can be attributed to granulomatous inflammation of the extracrani‐
al part of the nerve [9].
Recent  studies  have  found optic  neuropathy  to  be  a  more  common manifestation  than
previously  thought.  Patients  can  present  with  myriad  complaints,  ranging  from  blurry
vision and papilledema to retro-bulbar pain and pupillary abnormalities. Palsies of the 8th
cranial  nerve  also  occur,  leading  to  auditory  and  vestibular  problems.  Extra-ocular
movements can become impaired due to involvement of the 3rd, 4th, and 6th cranial nerves.
Olfactory involvement is  rare,  but  has been reported in some cases,  leading to anosmia
and impaired taste.
5.2. Neuroendocrine manifestation
Neuroendocrine  dysfunction is  often  seen in  neurosarcoidosis  patients,  causing them to
present  with  polyuria,  changes  in  thirst,  sleep,  appetite,  temperature,  or  libido.  The
hypothalamus and pituitary gland are also often affected, leading to thyroid, gonadal, and
adrenal- related symptoms. This usually occurs as a result of subependymal granuloma‐
tous infiltration of the 3rd  ventricle [9].  Other common symptoms include impaired taste
and smell,  slurred speech,  weakness  of  trapezius  and sternocleidomastoid muscles,  and
tongue deviation and atrophy. Additionally, carpal tunnel syndrome appears to occur more
often in sarcoidosis  patients,  than in the general  population.  Occasionally,  patients  may
present with the rare Heerfordt syndrome, characterized by fever,  uveitis,  parotid gland
swelling, and facial nerve palsy [10].
Neurosarcoidosis
http://dx.doi.org/10.5772/55118
185
5.3. Other CNS findings
In addition to the hypothalamus and pituitary gland, central nervous system involvement can
affect the cerebral cortex, cerebellum, and occasionally the spinal cord. This can occur due to
granulomatous inflammation in a perivascular pattern. Granulomas in various parts of the
brain parenchyma have even been known to mimic brain tumors such as gliomas, meningio‐
mas, and schwannomas.
Meningeal symptoms have been reported in a substantial number of patients; and can cause
many of the aforementioned symptoms. Examination of the cerebrospinal fluid typically
shows a mononuclear infiltrate and elevated protein. Cognitive and behavioral problems,
along with focal neurologic deficits can occur. If the spinal cord is affected, myelopathies and
radiculopathies can occur, and the cauda equina may be affected. Communicating and non-
communicating hydrocephalus have been seen in these patients, and sudden death can also
occur due to an acute obstruction of CSF flow. Seizures may also occur due to a variety of
causes. They are seen as an initial finding in 10% of patients. Sudden death can also occur with
involvement of the brainstem leading to central hypoventilation [9].
5.4. Peripheral neuropathy and myopathy
Patients can present with various types of peripheral neuropathies, including, but not limited
to mononeuropathy, sensory polyneuropathy, and acute and chronic inflammatory polyneur‐
opathy. Nerve biopsy typically shows noncaseating granulomas, but necrotizing vasculitis
may also be seen. Muscle involvement is commonly seen, and is typically secondary to
granulomas in the perimysium; however, only a very small number of patients are actually
symptomatic. Onset of myopathy usually occurs later in the course of the disease, after
involvement of other organ systems has already been noted. Patients may present with acute
myopathy, in a similar manner to polymyositis, or may have more chronic symptoms with
associated muscle wasting [9].
5.5. Atypical presentations
Sarcoidosis has been shown to affect many parts of both the central and peripheral nervous
systems, and patients present with a wide variety of neurological symptoms. Often this can
cause difficulties in making a diagnosis, as the reported symptoms are diverse and can mimic
several other disease processes, such as Guillain-Barre Syndrome, Multiple Sclerosis, and even
psychiatric diagnoses. In April 2012, Spiegel et al noted psychiatric manifestations, such as
delirium and psychosis, in about 20% of neurosarcoidosis patients, which is equivalent to
approximately 1% of all patients with sarcoidosis. Although this is a rare occurrence, these
patients can experience striking auditory and visual hallucinations and delusions [11].
Patients have also reportedly presented with hypersomnolence and hyperphagia consistent
with Kleine-Levine-Critchley syndrome [12]. In sum, as neurosarcoidosis can present in many
ways, clinicians should maintain a high index of suspicion for the disease, especially in those
patients who are not known to have sarcoidosis prior to presenting with neurological mani‐
festations. The disease can be very severe and often life-threatening.
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6. Diagnosis
Neurosarcoidosis has no pathognomonic sign, therefore it is a diagnosis of exclusion. This
presents a great challenge, especially when the patient does not previously have a confirmed
diagnosis of systemic sarcoidosis. The differential diagnosis encompasses a diverse number
of pathologies such as Bell’s palsy due to Lyme disease, optic neuropathy due to MS, tuber‐
culosis, carcinomatous or lymphomatous meningitis causing multiple cranial nerve palsies.
Additional pathologies include metastatic lesions, encephalopathy via syphilis or CNS
vasculitis, peripheral neuropathy, or parenchymal lesions such as astrocytomas. Therefore, it
is important to think of all the possibilities and rule them out [8].
If neurosarcoidosis is suspected, the patient should be evaluated for evidence of extraneural
disease due to the difficulty of obtaining nerve tissue for evaluation. It is imperative to check
the skin, lymph nodes and lungs. Other tests that may be useful include ophthalmologic
examination, endoscopic nasal and sinus examinations. Radiological tests include neuroimag‐
ing (discussed later) and chest x-ray or CT scan to search for hilar adenopathy or parenchymal
changes consistent with pulmonary sarcoidosis, serum angiotensin converting enzyme (ACE)
assays (nonspecific) and lumbar puncture to analyze CSF. CSF findings may show an increased
opening pressure, protein up to 250mg/dL, mononuclear pleocytosis, IgG elevation, oligoclo‐
nal bands, glucose normal or low; and CSF ACE is possibly elevated. CSF ACE levels have a
relative low sensitivity. Although most studies do not mention immunoglobulins levels in CSF,
there is evidence that elevation of immunoglobulin IgG with a high CSF to serum IgG index
may be common in CNS sarcoidosis [13]. CSF eosinophilia has also been reported as a
consequence of neurosarcoidosis, [14] but may also be present in other infections, inflamma‐
tory, and neoplastic conditions, including lepto-meningeal spread of gliomas [15]. Of note,
always be cautious of doing a LP in a patient that possibly has increase intracranial pressure.
If this is suspected, check for papilledema by using a fundoscope and MRI imaging preceding
the LP [8]. Routine laboratory tests may show hyperglobulinemia, hypercalcemia or elevation
of alkaline phosphatase [16]. Hypercalcemia occurs in approximately 13-20% of cases due to
high levels of 1,25-dihydroxy-vitamin D causing hyperabsorption of calcium [17,18].
Sarcoid lesions in  the CNS do not  differ  from those encountered in other  organs.  Most
cases of CNS sarcoidosis diagnosed by histology have shown variable degrees of menin‐
goencephalomyelitic  infiltration,  either  localized  or  widespread.  This  results  in  focal  or
disseminated meningeal nodules or plaques, and affecting particularly the basal mening‐
es.  Although  sarcoid  lesions  can  occur  almost  anywhere  in  the  central  nervous  struc‐
tures, most often they are located perivascularly, with varying degrees of associated gliosis
and fibroblast proliferation [3].
One may need to use other tests such as EEG, evoked potentials, and angiography to exclude
other causes. Another test, the Kveim-Siltzbach, is not standardized and is not available
universally. However, it can show positive granuloma results 4-6 weeks after injecting part of
a spleen from a patient with known sarcoidosis into the skin. According to a study by C K
Liam and A Menon, the Kveim-Siltzbach test can show false negative results when done in
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conjunction with corticosteroid use possibly due immunosuppressive effects. There is also
concern that HIV and hepatitis transmission could occur through this technique [8].
As a last resort, a biopsy is done of the meninges, brain, or spinal cord. Biopsies from extra‐
neural tissue are recommended as it is less risky, but if it is highly suspected and a person with
known sarcoidosis with neurologic involvement is deteriorating despite therapy, the neural
tissue can be sampled [19]. Most common sites include the meninges and mass lesions.
7. Neuroimaging
Neurosarcoidosis does not have a specific finding on imaging that can assure the diagnosis.
However, neuroimaging along with neurologic evaluation, CSF analysis, biopsy and others
can aid in making the diagnosis. Oftentimes, it is a brain contrast-enhanced MRI and CSF
analysis that gives the presumptive diagnosis. Contrast MRI allows one to visualize meningeal
or parenchymal involvement of active inflammation with disruption of the blood brain barrier
as well as masses and hydrocephalus.
Figure 1. Noncaseating granuloma in parietal lobe showing the granuloma surrounded by epithelioid cells and nodu‐
lar inflammatory infiltrates (hematoxylin and eosin, 10x). [35]
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As mentioned previously, cranial nerve palsies are the most common presentation in neuro‐
sarcoidosis, which can be seen on MRI with inflammation along with spinal cord involvement
as well [20]. There have been studies done in which enhanced CT was shown to be normal,
but the enhanced MRI was abnormal, implying greater sensitivity of MRI for detection
neurosarcoidosis lesions [21].
In neurosarcoidosis, leptomeningeal disease is a common pattern of involvement, which may
be localized or widespread. Less commonly, granulomatous masses can be found within the
cerebral parenchyma. There have been cases showing patients with cranial nerve palsies
demonstrating clear evidence of focal meningeal disease on gadolinium-DTPA enhanced MRI
brain scans. Neurosarcoidosis is difficult to diagnose when patients have no evidence of
granulomatous disease outside the nervous system because of the difficulty of obtaining tissue
for histological examination. Therefore, primarily neurological evaluation, neuroimaging and
lumbar puncture are done. However, diffuse meningeal infiltration particularly in the skull
base region is frequently found at necropsy. Two cases presented by Khaw et al showed
Gadolinium-DTPA enhanced MRI’s in patients with cranial nerve palsies; one with solely
cranial nerve palsies and the other along with gynecologic manifestations. In both of these
cases, the meninges were affected by the disease and patients presented with multiple lower
cranial nerve palsies, which was not picked up by CT or non-contrast MRI [22].
According to Pawate et al, a study done on 54 cases of neurosarcoidosis, the majority (23%)
were found to have intraparenchymal T2 hyperintense lesions on brain MRI. 19% were found
to have meningeal involvement seen with gadolinium enhanced MRI. Few of these cases
showed intracranial masses, normal brain or solely spinal cord involvement on MRI [23].
When the CNS is involved, brain enhanced MRI and CSF studies are sensitive in the detection
of CNS inflammation, however they lack specificity. This continues to make diagnosing
neurosarcoidosis a clinical challenge.
8. Management of neurosarcoidosis
While sarcoidosis is a progressive autoimmune disease and there is currently no cure,
symptomatic treatment is available. Corticosteroids have become the treatment of choice for
neurosarcoidosis. The dosage and duration of therapy varies based upon the type and severity
of the symptoms. For instance, patients who present with peripheral facial nerve palsy or
meningeal symptoms are given about 0.5mg/kg/day of prednisone for two weeks. On the other
hand, a patient with myopathy is given the same dosage for four weeks, and a patient with a
mass lesion or symptomatic hydrocephalus is given two to three times this amount for four
weeks. Very severe cases of neurosarcoidosis benefit from IV methylprednisone 20mg/kg/day
for three days, followed by 1-1.5mg/kg/day of prednisone for two to four weeks [24].
The exact mechanism by which corticosteroids have benefited patients with neurosarcoidosis
is unclear, but is generally believed to be secondary to its anti-inflammatory and immunomo‐
dulatory effects. Corticosteroids are known to prevent leukocytes from gaining access to sites
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 (a) (b) 
Figure 2. Neurosarcoidosis involving the pituitary-hypothalamic axis. T-1 gadolinium-enhanced Axial (a) and coronal
(b) views shows an area of abnormal enhancement involving the sellar, suprasellar regions and the interpeduncular
cistern. The diagnosis was confirmed by a biopsy [3].
 
(a) (b) 
Figure 3. Meningeal neurosarcoidosis. Axial (a) and coronal (b) MRI T-1 weighted images post infusion of gadolinium
DTPA in a patient with systemic sarcoidosis show thickening and enhancement of the dura surrounding the left hemi‐
sphere [3].
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of inflammation, interfere with their function along with that of endothelial cells and fibro‐
blasts, and suppress production of various humoral factors [25]. It is always important to keep
in mind, however, that as with all medications, corticosteroids are not without side effects.
Common side effects of corticosteroids include cognitive and personality changes, weight gain
with central obesity, development of striae, diabetes mellitus, cataracts and predisposition to
various infections. Cardiovascular effects are also known to occur, such as hypertension,
dyslipidemia, and increased risk of myocardial infarction and stroke. Patients receiving long
term corticosteroid therapy are at risk for osteoporotic fractures, especially in the setting of
other general risk factors such as being over age 60 or having osteoporosis prior to corticoste‐
roid treatment. Additionally, avascular necrosis, especially of the hip, has been known to occur
in a number of patients [1]. Therefore, it is important to carefully monitor the dosage, and to
always use the lowest possible effective dose. If treatment with corticosteroids is to be
discontinued, it is essential to decrease the dose gradually. Abrupt discontinuation of corti‐
costeroid therapy can cause adrenal insufficiency.
8.1. Alternative therapies for refractory neurosarcoidosis
Several therapies have been proposed for those patients in whom corticosteroid treatment is
unsuccessful, or in those who have contraindications to treatment. Many of these studies have
shown methotrexate to be an effective treatment. Methotrexate has been successful in two-
thirds of sarcoidosis patients regardless of the organ systems that are affected. In one study,
EE Lower et al observed 554 sarcoidosis patients, of which 71 had neurosarcoidosis. They
found that treatment with methotrexate and cyclophosphamide was associated with higher
response rates than treatment with corticosteroids only [26].
In 2007, TF Scott et al used aggressive therapy with corticosteroids and alternative immuno‐
suppressants in 48 patients. Over half of these cases had favorable outcomes [27]. Later, in
2011, G Androdias et al observed a small group of patients with neurosarcoidosis, and found
evidence suggesting that Mycophenolate mofetil was effective in treatment of CNS symptoms.
The agent was also found to have a steroid sparing effect and was better tolerated than several
other immunosuppressive agents [28]. Additional studies have shown anti-TNF agents such
as infliximab to be effective; and cytokine modulators such as thalidomide and pentoxifylline
have also been used in a limited number of cases [29].
8.2. Other treatments
Surgical resection of CNS mass lesions is usually not recommended, unless the mass persists
or continues to enlarge despite appropriate immunomodulatory therapy. If the patient
presents with symptomatic hydrocephalus, a ventriculoperitoneal shunt can be placed. It is
important to continue immunosuppressive treatment following placement of the shunt as
inflammation can lead to obstruction. Cranial or spinal irradiation is suggested in refractory
cases if no response is seen with corticosteroids and at least two other agents [30]. Additionally,
symptom-specific treatment may be needed, such as hormone replacement therapy for
hypopituitarism, and antipsychotics for patients with psychosis.
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9. Prognosis of neurosarcoidosis
While many patients with neurosarcoidosis have a monophasic illness, relapsing-remitting
and progressive disease patterns are also seen. RA Luke et al followed 25 patients with
neurosarcoidosis for a minimum of 5 years or until death. 68% of the patients were found to
have the monophasic pattern and 32% had a relapsing pattern [31]. The authors also noted that
relapses were more common in patients with cerebral symptoms and in those presenting with
hydrocephalus. Furthermore, relapses occurred more frequently in those who were taking
smaller doses of corticosteroids (10mg or less).
Although the long term outcomes in neurosarcoidosis patients have not yet been clearly
defined in studies, some general conclusions can be made. Patients with peripheral facial nerve
palsy often show improvement within 2-4 weeks. Some patients with optic neuropathy show
improvement, while others with a more progressive disease pattern can become blind. In 1999,
G.A. Christoforidis et al conducted a retrospective study of 461 patients with sarcoidosis,
confirmed on biopsy. These researchers reported that patients with optic nerve involvement
often did not respond as well to corticosteroid treatment as those with other CNS manifesta‐
tions did. The researchers suggest that because the other cranial nerves are surrounded by
Schwann cells, they can regenerate more easily than the optic nerve, whose myelin sheath is
produced by oligodendrocytes [32].
Symptoms such as peripheral neuropathy and myopathy also tend to follow a more chronic
and progressive pattern. Aseptic meningitis usually improves within a few weeks, yet CSF
abnormalities (asymptomatic chronic pleocytosis) can persist for some time after. Mass lesions
often persist for some time, but can also resolve on occasion. Additionally, patients with
encephalopathy often exhibit a progressive pattern. Typically immunomodulatory medica‐
tions are not helpful in patients with endocrinopathies, and these patients need to be treated
with hormonal replacement therapy. Also, a series of 68 patients were followed by JP Zajicek
et al in 1998, who noted spinal cord involvement in 28% of the patients [33]. The authors
concluded that spinal cord disease had a poorer prognosis, as a significant percentage of these
patients were found to have deteriorated at follow-up. Patients with seizures have historically
been shown to have a poorer prognosis, but more recent studies have disproved this [8].
In general, as the outcome in patients with neurosarcoidosis depends on the severity and types
of neurological symptoms, it is difficult to make a conclusive statement regarding the prog‐
nosis of the disease. Reportedly, about 10% of patients with neurosarcoidosis die of the disease,
typically secondary to CNS parenchymal involvement, hydrocephalus, or other severe
symptoms; or due to immune-compromise secondary to treatment.
10. Concluding remarks
Neurosarcoidosis can range from mild to life threatening; and can affect any part of the central
and peripheral nervous systems. It can present at any point during the course of the disease
Sarcoidosis192
process. Many patients do not experience neurological symptoms until the disease has
progressed for some time, and systemic symptoms are present. Other patients have neuro‐
logical manifestations of the disease at the time of initial presentation. Overall, however,
neurosarcoidosis only represents a small portion of the total population of patients with a
diagnosis of sarcoidosis - about 5%. If patients present with neurological symptoms, with no
prior diagnosis of sarcoidosis, it might prove difficult for clinicians to make a diagnosis. This
is because these symptoms are quite general and can be seen with a multitude of other diseases.
Patients have been reported to have not only general cranial nerve palsies and peripheral
neuropathies, but also have been known to present with meningeal symptoms, hydrocephalus,
seizures, and even psychosis.
Since the exact cause of neurosarcoidosis is not known, it is important to be aware of any clinical
signs early on. It is also important to differentiate it from other diseases with similar manifes‐
tations, such as multiple sclerosis due to differences in management and treatment. There are
many clinical and lab tests available, as well as imaging that can help determine if one has
neurosarcoidosis. Although there is no pathgnomonic sign, brain contrast MRI is a vital tool
along with CSF analysis that can give a presumptive diagnosis. They are highly sensitive,
although lack specificity, which makes it difficult to definitively diagnose it. Gullapalli and
Phillips found a sensitivity of brain MRI of about 82–97% for MS; for CSF abnormality and
CSF ACE, sensitivity was 50–80% and 50%, respectively [34]. The most definitive diagnosis
can be made from histological analysis of neural tissue via biopsy if there is still doubt despite
the other tests or at autopsy. However, it is used as a last resort due to being the most invasive
method.
As with other sarcoidosis patients, corticosteroids are the main treatment for neurosarcoidosis.
However, some manifestations are more responsive to steroids than others. Additionally,
many patients taking corticosteroids for an extended period of time often experience serious
side effects; and there are also several contraindications to taking these medications. For this
reason, several alternative therapies have been proposed for sarcoidosis patients, and several
studies have found methotrexate and cyclophosphamide to be especially effective in treatment
of neurological symptoms. Many other immunomodulatory medications have also been
shown to be effective along with various symptom- specific treatments.
While many studies have been conducted with regards to the long term outcomes of neuro‐
sarcoidosis patients, no definitive conclusions can be made as yet. However, the prognosis for
these patients is mainly dependent on the neurological manifestations they experience.
Patients with cranial nerve palsies, and particularly optic neuropathies, have been shown in
many cases to respond well to corticosteroid treatment. More serious symptoms on the other
hand, such as seizures and spinal cord involvement generally suggest a poor prognosis.
However, one must also keep in mind, that various disease patterns have been reported in
neurosarcoidosis patients. Neurosarcoidosis may present as a monophasic, relapsing-remit‐
ting, or chronic progressive pattern. Thus, additional studies need to be conducted before any
conclusive statements can be made regarding the outlook for patients with neurosarcoidosis.
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Nomenclature
CNS: central nervous system
CD4: cluster of differentiation 4
Th1: type 1 helper cells
HLA: human leukocyte antigen
MS: multiple sclerosis
ACE: angiotensin converting enzyme
CSF: cerebrospinal fluid
LP: lumbar puncture
MRI: magnetic resonance imaging
HIV: human immunodeficiency virus
EEG: electroencephalogram
CT: computed tomography
DTPA: diethylene triamine pentaacetic acid
Mg: milligrams
Kg: kilograms
IV: intravenous
TNF: tumor necrosis factor
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